Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge

被引:21
作者
Antonis, Adriaan F. G.
van der Most, Robbert G.
Suezer, Yasemin
Stockhofe-Zurwieden, Norbert
Daus, Franz
Sutter, Gerd
Schrijver, Remco S.
机构
[1] Div Infect Dis, Anim Sci Grp, NL-8200 AB Lelystad, Netherlands
[2] Univ Utrecht, Fac Med Vet, Dept Infect Dis & Immunol, Div Immunol, Utrecht, Netherlands
[3] GSF Munich, Inst Mol Virol, D-81675 Munich, Germany
[4] Paul Ehrlich Inst, Dept Virol, D-63225 Langen, Germany
关键词
RSV; MVA; FI-RSV; vaccine efficacy and safety; vaccine mediated enhanced disease; IgE; humoral immune responsiveness; cellular responsiveness;
D O I
10.1016/j.vaccine.2007.04.002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Respiratory syncytial virus (RSV) is a major cause of severe respiratory disease in infants and calves. Bovine RSV (bRSV) is a natural pathogen for cattle, and bRSV infection in calves shares many features with the human infection. Thus, bRSV infection in cattle provides the ideal setting to evaluate the safety and efficacy of novel RSV vaccine strategies. Here, we have evaluated the efficacy and safety of modified vaccinia virus Ankara (rMVA)-based vaccine candidates, expressing the bovine RSV-F protein, either or not in combination with the G protein, in colostrums-deprived SPF calves born by caesarean section. Vaccination induced bRSV-specific IgG and CD8 T cell responses. Importantly, no IgE responses were detected. After bRSV challenge, rMVA vaccinated calves experienced less severe symptoms of lower respiratory tract disease compared to the mock-immunized control group. Immunized animals showed reduced pulmonary virus loads, and no eosinophilic infiltration or enhanced respiratory distress. In conclusion, candidate rMVA/bRSV vaccines induced protective and safe immune responses in calves. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4818 / 4827
页数:10
相关论文
共 49 条
[1]  
ANTONIS AF, UNPUB BOVINE RESP SY
[2]   Kinetics of antiviral CD8 T cell responses during primary and post-vaccination secondary bovine respiratory syncytial virus infection [J].
Antonis, AFG ;
Claassen, EAW ;
Hensen, EJ ;
de Groot, RJ ;
de Groot-Mijnes, JDF ;
Schrijver, RS ;
Van der Most, RG .
VACCINE, 2006, 24 (10) :1551-1561
[3]   Vaccine-induced immunopathology during bovine respiratory syncytial virus infection: Exploring the parameters of pathogenesis [J].
Antonis, AFG ;
Schrijver, RS ;
Daus, F ;
Steverink, PJGM ;
Stockhofe, N ;
Hensen, EJ ;
Langedijk, JPM ;
van der Most, R .
JOURNAL OF VIROLOGY, 2003, 77 (22) :12067-12073
[4]   Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins:: implications for use as a human vaccine [J].
Blanchard, TJ ;
Alcamí, A ;
Andrea, P ;
Smith, GL .
JOURNAL OF GENERAL VIROLOGY, 1998, 79 :1159-1167
[5]   FIELD EVALUATION OF A RESPIRATORY SYNCYTIAL VIRUS VACCINE AND A TRIVALENT PARAINFLUENZA VIRUS VACCINE IN A PEDIATRIC POPULATION [J].
CHIN, J ;
MAGOFFIN, RL ;
SHEARER, LA ;
SCHIEBLE, JH ;
LENNETTE, EH .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1969, 89 (04) :449-+
[6]  
Coghe J, 2000, VET J, V160, P139
[7]   Respiratory syncytial virus: Reverse genetics and vaccine strategies [J].
Collins, PL ;
Murphy, BR .
VIROLOGY, 2002, 296 (02) :204-211
[8]   Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals [J].
Cosma, A ;
Nagaraj, R ;
Bühler, S ;
Hinkula, J ;
Busch, DH ;
Sutter, G ;
Goebel, FD ;
Erfle, V .
VACCINE, 2003, 22 (01) :21-29
[9]   Evaluation of BBG2Na in infant macaques:: specific immune responses after vaccination and RSV challenge [J].
de Waal, L ;
Power, UF ;
Yüksel, S ;
van Amerongen, G ;
Nguyen, TN ;
Niesters, HGM ;
de Swart, RL ;
Osterhaus, ADME .
VACCINE, 2004, 22 (08) :915-922
[10]   Vaccination of infant macaques with a recombinant modified vaccinia virus Ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology [J].
de Waal, L ;
Wyatt, LS ;
Yüksel, S ;
van Amerongen, G ;
Moss, B ;
Niesters, HGM ;
Osterhaus, ADME ;
de Swart, RL .
VACCINE, 2004, 22 (08) :923-926